Surgical AVR with 19-mm third-generation bioprostheses in small aortic annulus patients showed overall survival rates of 93.0% at 1 year, 87.0% at 3 years, and 85.7% at 5 years, with stable hemodynamics and 28% moderate-to-severe prosthesis-patient mismatch.
Observational
No
Patients undergoing aortic valve replacement (AVR) in Japan
19-mm bioprostheses
Clinical outcomes and hemodynamic performance
Background: Data on the clinical outcomes and hemodynamic performance of the smallest commercially available bioprostheses (19 mm) in Japan for aortic valve replacement (AVR) remain limited.
Building similarity graph...
Analyzing shared references across papers
Loading...
T. Gyoten
Yuta Kanazawa
Yu Kumagai
Circulation Reports
Saitama Medical University
Building similarity graph...
Analyzing shared references across papers
Loading...
Gyoten et al. (Thu,) conducted a observational in Adults with small aortic annulus undergoing surgical aortic valve replacement (SAVR) with 19-mm third-generation bioprostheses (n=187). Surgical aortic valve replacement with 19-mm third-generation bioprostheses (Avalus, Magna, Epic, Inspiris, Mosaic) was evaluated on All-cause death after SAVR. Surgical AVR with 19-mm third-generation bioprostheses in small aortic annulus patients showed overall survival rates of 93.0% at 1 year, 87.0% at 3 years, and 85.7% at 5 years, with stable hemodynamics and 28% moderate-to-severe prosthesis-patient mismatch.
www.synapsesocial.com/papers/69a7672bbadf0bb9e87dfda5 — DOI: https://doi.org/10.1253/circrep.cr-25-0307